Fundraising FoxWugen
St. Louis, US · Founded 2018 · Delaware corporation · 10 known investors
Find your way into Wugen
Sign up to see every warm intro you have to Wugen
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Wugen team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Allotera (formerly Wugen) develops allogeneic T-cell therapies. The company focuses on cell and gene therapy approaches for treating disease.
Founders & leadership
AK
Ayman KabakibiExecutiveHe has spent over two decades in pharmaceutical and biotech drug development, with experience spanning cell therapy modalities, multiple therapeutic areas, and regulatory interactions.
KV
Keith VendolaExecutive
DM
Daniel M KempExecutive
MC
Matthew CooperNamed on SEC filing
JK
Jan K DavidsonNamed on SEC filing
Board
NM
DD
Drew DennisonBoard director
NO
BM
BH
Bosun HauBoard director
Investors · 10
Aisling Capitallisted by Aisling CapitalNew York
How we know: Aisling Capital's portfolio page · clinicaltrialsarena.com · Not right? Tell us
Alpha Wave Globallisted by Alpha Wave GlobalMiami
How we know: Alpha Wave Global's portfolio page · Not right? Tell us
BioGenerator Ventureslisted by BioGenerator VenturesSt. Louis · $50K – $250K
How we know: BioGenerator Ventures's portfolio page · Not right? Tell us
RiverVest Venture Partnerslisted by RiverVest Venture PartnersSt. Louis · $500K – $3M
How we know: RiverVest Venture Partners's portfolio page · clinicaltrialsarena.com · Not right? Tell us
AbingworthreportedLondon · $15M – $30Mvia Bali Muralidhar · board
How we know: board seat on SEC Form D · funding news · clinicaltrialsarena.com · Not right? Tell us
Also in the syndicate · 2
Lightchain CapitalTybourne Capital Management
Funding
SEC filings, press & company announcements$294M disclosed across 4 rounds · 2020–2026
- $35MraisedJul 2026 · 2 sourcesSource ↗
▶$123.3MraisedJul 2026 · 20 investors · Other Health CareRule 506(b)
▶$123.3MraisedJul 2026 · 20 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Niall O'DonnellDirector
- Bali MuralidharDirector
- Peter KienerDirector
- Drew DennisonDirector
- Kevin LiDirector
- Bosun HauDirector
- Matthew CooperExecutive Officer
- Ayman KabakibiExecutive Officer
- Natalie MountDirector
- Kumar SrinivasanExecutive Officer, Director
- Cherry ThomasExecutive Officer
- Offering amount
- $163M
- Amount sold
- $123.3M
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$98.5MraisedJul 2021 · 27 investors · Other Health CareRule 506(b)
▶$98.5MraisedJul 2021 · 27 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Daniel M KempExecutive Officer, Director
- Bali MuralidharDirector
- Ayman KabakibiExecutive Officer
- John P McKearnDirector
- Bosun HauDirector
- Peter KienerDirector
- Jan K DavidsonExecutive Officer
- Matthew CooperExecutive Officer
- Kevin LiDirector
- Drew DennisonDirector
- Offering amount
- $172M
- Amount sold
- $98.5M
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$37.2MraisedJul 2021 · 6 investors · Other Health CareRule 506(b)
▶$37.2MraisedJul 2021 · 6 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Ayman KabakibiExecutive Officer
- Jan K DavidsonExecutive Officer
- Kevin LiDirector
- John P. McKearnDirector
- Matthew CooperExecutive Officer
- Bali MuralidharDirector
- Peter KienerDirector
- Drew DennisonDirector
- Bosun HauDirector
- Daniel M KempExecutive Officer, Director
- Offering amount
- $37.2M
- Amount sold
- $37.2M
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 6
Biogen IdecBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.
PepGenPepGen is a clinical-stage biotech company developing oligonucleotide therapies for neuromuscular and neurological diseases using its Enhanced Delivery Oligonucleotide (EDO) platform to improve tissue penetration and uptake in muscle tissues.
AmgenAmgen is an independent biotechnology company that uses science and technology, including machine learning and human genetic data, to research and develop treatments for serious diseases such as cancer, heart disease, asthma, and osteoporosis. Its Danish operation, Amgen Danmark, focuses on improving health outcomes for patients and their families in Denmark.
UrogenUroGen is a biotech company developing treatments for urothelial and specialty cancers using a proprietary sustained-release hydrogel platform technology. The company commercializes approved therapies for bladder and upper tract cancers, with additional candidates in development.
CompugenCompugen develops immuno-oncology therapeutics using Unigen, a computational platform that combines scientific research with AI/ML to identify novel drug targets and design first-in-class antibody drugs. Its therapeutic antibodies targeting novel pathways are being evaluated in multiple clinical trials.
NervGen PharmaNervGen is a clinical-stage biotech company developing therapies for neurological conditions, with a focus on spinal cord injury and neurorepair. It maintains a drug pipeline and operates as a publicly traded company.
Companies working in the same space as Wugen.
In the news
Frequently asked questions
- What does Wugen do?
- Allotera (formerly Wugen) develops allogeneic T-cell therapies. The company focuses on cell and gene therapy approaches for treating disease.
- Who are Wugen's investors?
- Wugen's investors include Aisling Capital, Alpha Wave Global, BioGenerator Ventures, RiverVest Venture Partners, Abingworth, Fidelity Investments, Intermediate Capital Group, LYZZ Capital.
- How much funding has Wugen raised?
- Wugen has disclosed $294M raised across 4 rounds.
- Where is Wugen headquartered?
- Wugen is headquartered in St. Louis, US.